Novus Biologicals, Inc Ranked Number 22nd in Deloitte's Technology Fast 50 Program for Colorado.

Littleton, CO, October 24, 2008 — Novus Biologicals, Inc. has been named to Deloitte's prestigious Technology Fast 50 Program for Colorado, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area by Deloitte LLP, one of the nation’s leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2003–2007. Novus Biologicals’ CEO Karen Padgett credits the employees and quality products with the company's 151% percent revenue growth from 2003–2007. Novus Biologicals’ increase in revenues of 151% percent from 2003 to 2007 resulted in a 22nd ranking in the Technology Fast 50 for Colorado. The average increase in revenues among companies who made the Technology Fast 50 for this region was 507% percent. To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2003 and $5,000,000 in 2007, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify. Companies from the regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Technology Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte’s Technology Fast 50 or Technology Fast 500 programs, visit About Novus Biologicals The mission of Novus Biologicals, Inc. is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals was organized to provide the biological research community with a mechanism for commercializing unique biological materials. We also focus on continually monitoring scientific trends and supply materials to serve these trends. By serving niche and emerging markets, Novus Biologicals has become specialists in markets and has formed and will continue to form ongoing partnerships with our customers. PR Contact: Bryan Tinsley, Novus Biologicals, Inc., 303-730-1950, About Deloitte As used in this document, “Deloitte” means Deloitte LLP. Please see for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

Release Date: 
Tuesday, October 28, 2008 - 06:00